Novacyt S.A [ALNOV] vs Diagnostic Medical [ALDMS] Detailed Stock Comparison
Novacyt S.A
Euronext
Loading...
Diagnostic Medical
Euronext
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Novacyt S.A wins in 5 metrics, Diagnostic Medical wins in 11 metrics, with 0 ties. Diagnostic Medical appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Novacyt S.A | Diagnostic Medical | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -0.80 | -9.57 | Diagnostic Medical |
| Price-to-Book Ratio | 0.70 | 2.18 | Novacyt S.A |
| Debt-to-Equity Ratio | 24.81 | 141.76 | Novacyt S.A |
| PEG Ratio | 1.82 | N/A | N/A |
| EV/EBITDA | -1.31 | 12.44 | Novacyt S.A |
| Profit Margin (TTM) | -212.73% | -5.90% | Diagnostic Medical |
| Operating Margin (TTM) | -84.87% | 1.90% | Diagnostic Medical |
| EBITDA Margin (TTM) | N/A | 1.90% | N/A |
| Return on Equity | -57.28% | -20.20% | Diagnostic Medical |
| Return on Assets (TTM) | -10.19% | -0.94% | Diagnostic Medical |
| Free Cash Flow (TTM) | $-12.74M | $30,000 | Diagnostic Medical |
| 1-Year Return | -59.48% | 38.14% | Diagnostic Medical |
| Price-to-Sales Ratio (TTM) | 1.78 | 0.74 | Diagnostic Medical |
| Enterprise Value | $17.03M | $44.00M | Diagnostic Medical |
| EV/Revenue Ratio | 0.75 | 0.90 | Novacyt S.A |
| Revenue per Share (TTM) | $0 | $2 | Diagnostic Medical |
| Earnings per Share (Diluted) | $-0.64 | $-0.13 | Diagnostic Medical |
| Beta (Stock Volatility) | 0.10 | 0.88 | Novacyt S.A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Novacyt S.A vs Diagnostic Medical Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Novacyt S.A | 0.21% | 0.00% | 0.00% | -18.97% | -21.67% | -22.95% |
| Diagnostic Medical | 0.00% | -4.29% | -2.19% | 13.56% | 36.73% | 69.62% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Novacyt S.A | -59.48% | -56.48% | -86.05% | -88.99% | -94.46% | -94.46% |
| Diagnostic Medical | 38.14% | 22.94% | -12.99% | -44.17% | -37.09% | -37.09% |
Performance & Financial Health Analysis: Novacyt S.A vs Diagnostic Medical
| Metric | ALNOV | ALDMS |
|---|---|---|
| Market Information | ||
| Market Cap | €34.84M | €36.03M |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 200,980 | 24,800 |
| 90 Day Avg. Volume | 181,413 | 37,478 |
| Last Close | €0.47 | €1.34 |
| 52 Week Range | €0.42 - €1.19 | €0.64 - €1.46 |
| % from 52W High | -60.22% | -7.90% |
| All-Time High | €13.96 (Oct 26, 2020) | €3.88 (Feb 17, 2014) |
| % from All-Time High | -96.63% | -65.46% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | N/A |
| Quarterly Earnings Growth | N/A | N/A |
| Financial Health | ||
| Profit Margin (TTM) | -2.13% | -0.06% |
| Operating Margin (TTM) | -0.85% | 0.02% |
| Return on Equity (TTM) | -0.57% | -0.20% |
| Debt to Equity (MRQ) | 24.81 | 141.76 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €0.68 | €0.62 |
| Cash per Share (MRQ) | €0.43 | €0.26 |
| Operating Cash Flow (TTM) | €-11,367,175 | €3.60M |
| Levered Free Cash Flow (TTM) | €7.14M | €-2,832,750 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Novacyt S.A vs Diagnostic Medical
| Metric | ALNOV | ALDMS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -0.80 | -9.57 |
| Forward P/E | 1.82 | 33.50 |
| PEG Ratio | 1.82 | N/A |
| Price to Sales (TTM) | 1.78 | 0.74 |
| Price to Book (MRQ) | 0.70 | 2.18 |
| Market Capitalization | ||
| Market Capitalization | €34.84M | €36.03M |
| Enterprise Value | €17.03M | €44.00M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.75 | 0.90 |
| Enterprise to EBITDA | -1.31 | 12.44 |
| Risk & Other Metrics | ||
| Beta | 0.10 | 0.88 |
| Book Value per Share (MRQ) | €0.68 | €0.62 |
Financial Statements Comparison: Novacyt S.A vs Diagnostic Medical
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ALNOV | ALDMS |
|---|---|---|
| Revenue/Sales | N/A | N/A |
| Cost of Goods Sold | N/A | N/A |
| Gross Profit | N/A | N/A |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | N/A | N/A |
| EBITDA | N/A | N/A |
| Pre-Tax Income | N/A | N/A |
| Income Tax | N/A | N/A |
| Net Income (Profit) | N/A | N/A |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ALNOV | ALDMS |
|---|---|---|
| Cash & Equivalents | €35.25M | €5.34M |
| Total Current Assets | €45.58M | €30.30M |
| Total Current Liabilities | €7.20M | €23.50M |
| Long-Term Debt | €12.29M | €11.52M |
| Total Shareholders Equity | €55.43M | €14.16M |
| Retained Earnings | €-13.54M | €-2.88M |
| Property, Plant & Equipment | €0 | €348,000 |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ALNOV | ALDMS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ALNOV | ALDMS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 200,980 | 24,800 |
| Average Daily Volume (90 Day) | 181,413 | 37,478 |
| Shares Outstanding | 81.73M | 20.03M |
| Float Shares | 70.58M | 15.44M |
| % Held by Insiders | 0.00% | 0.24% |
| % Held by Institutions | 0.00% | 0.00% |
Dividend Analysis & Yield Comparison: Novacyt S.A vs Diagnostic Medical
| Metric | ALNOV | ALDMS |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |